1-10 of 10
Elisabeth Niemoeller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Juan Pablo Frias, JaeDuk Choi, Julio Rosenstock, Luiza Popescu, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Seungjae Baek
Journal: Diabetes Care
Diabetes Care 2022;45(7):1592–1600
https://doi.org/10.2337/dc21-2656
Published: 06 July 2022
View article titled, Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
Open the PDF for Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial in another window
Journal Articles

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L. Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2021;44(3):774–780
https://doi.org/10.2337/dc20-2023
Published: 19 January 2021
View article titled, Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Open the PDF for Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study in another window
Journal Articles

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial

Thomas Danne, William V. Tamborlane, Oleg A. Malievsky, Denise R. Franco, Tomoyuki Kawamura, Marek Demissie, Elisabeth Niemoeller, Harmonie Goyeau, Marek Wardecki, Tadej Battelino
Journal: Diabetes Care
Diabetes Care 2020;43(7):1512–1519
https://doi.org/10.2337/dc19-1926
Published: 19 May 2020
View article titled, Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Open the PDF for Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial in another window
Journal Articles

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

Hirotaka Watada, Akane Takami, Robert Spranger, Atsushi Amano, Yasuhiro Hashimoto, Elisabeth Niemoeller
Journal: Diabetes Care
Diabetes Care 2020;43(6):1249–1257
https://doi.org/10.2337/dc19-2452
Published: 15 April 2020
View article titled, Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
Open the PDF for Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial in another window
Journal Articles

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

Lawrence Blonde, Julio Rosenstock, Stefano Del Prato, Robert Henry, Naim Shehadeh, Juan Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2019;42(11):2108–2116
https://doi.org/10.2337/dc19-1357
Published: 17 September 2019
View article titled, Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Open the PDF for Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980

Vanita R. Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M. Bergenstal, on behalf of the LixiLan-L Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(6):809
https://doi.org/10.2337/dc17-er06d
Published: 20 April 2017
View article titled, Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980
Open the PDF for Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39: 1972–1980 in another window
Journal Articles

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035

Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies, on behalf of the LixiLan-O Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(6):809
https://doi.org/10.2337/dc17-er06c
Published: 18 April 2017
View article titled, Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035
Open the PDF for Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39: 2026–2035 in another window
Journal Articles

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M. Bergenstal, on behalf of the LixiLan-L Trial Investigators
Journal: Diabetes Care
Diabetes Care 2016;39(11):1972–1980
https://doi.org/10.2337/dc16-1495
Published: 20 September 2016
View article titled, Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
Open the PDF for Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies, on behalf of the LixiLan-O Trial Investigators
Journal: Diabetes Care
Diabetes Care 2016;39(11):2026–2035
https://doi.org/10.2337/dc16-0917
Published: 15 August 2016
View article titled, Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
Open the PDF for Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Matthew C. Riddle, MD, Ronnie Aronson, MD, FRCPC, FACE, Philip Home, DPHIL, DM, FRCP, Michel Marre, MD, PHD, Elisabeth Niemoeller, MD, Patrick Miossec, MD, Lin Ping, MD, Jenny Ye, Julio Rosenstock, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2489–2496
https://doi.org/10.2337/dc12-2454
Published: 13 August 2013
View article titled, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle>
Open the PDF for Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle> in another window
Includes: Supplementary data